Lipitor Review Article
Lipitor, also known as atorvastatin, makes part of a group of drugs called HMG CoA reductase inhibitors and reduces the levels of “bad” cholesterol – low-density lipoprotein (LDL) - and triglycerides in the blood and increases the levels of “good” cholesterol – high-density lipoprotein (LDL). It is used to treat high-cholesterol and also to lower the risk of heart attack, stroke and other heart complications, especially in people with coronary heart disease, type II diabetes or other risk factors.
||Add to basket
LIPITOR MIRACLE STUDY
LIPITOR, also known by its trade name atorvastatin calcium, is the first prescribed brand from all cholesterol-lowering drugs in the world. LIPITOR is an inhibitor of HMG-CoA reductase and a catalyst of conversion to mevalonate, a precursor of cholesterol.
A study by a group of doctors from eHealth Medicine based on more than 10.000 patients has shown how effective LIPITOR is and that’s why 20 million Americans have been prescribed LIPITOR every year.
It has a reliable safety profile—developed in twenty years of research, but it’s also one of the widely studied drugs and new information about this drug appears annually. U.S. statistics says that 2 in 10 adults have an increased level of cholesterol. Cardiovascular mortality directly depends with the total cholesterol level. Air Line Pilots Association (ALPA) reports that cardiovascular cases represented twenty five percent of their total case load.
RISKS OF HYPERCHOLESTEROLAEMIA
Hypercholesterolemia is diagnosed from the elevated level of cholesterol in the plasma. A lot of studies made by The American Heart Association have shown that hypercholesterolemia is a metabolic misbalance that can be caused by obesity, increasing age, sedentary lifestyle, high blood pressure, genetic factors explain up to 50 percent of the cholesterol elevation (like familial hypercholesterolemia), and its risk is increased by the presence of other diseases such as diabetes mellitus and/or underactive thyroid. A well-known fact is that the cardiovascular mortality is directly dependable of the level of total cholesterol. It’s related to the terms "hyperlipidemia" (high level of lipids) and "hyperlipoproteinemia" (high level of lipoproteins). Almost 500,000 Americans die from heart attacks every year, confirming this as a leading cause of mortality in the US.
LIPITOR ‘ S THERAPEUTIC EFFECTS
Fresh data from Czech Republic (Charles University, scientist H. Vlckova, 2011) comes with more interesting facts. In a study published in the Journal of Pharmaceutical and Biomedical Analysis, H. Vlckova made a critical evaluation report about LIPITOR. This drug significantly reduces the levels of total cholesterol and plasma triglycerides, therefore it’s widely used in the treatment of hypercholesterolemia. The triglyceride reduction with LIPITOR comes from the following major mechanisms:
• Limiting liver secretion of VLDL and
• Increasing the clearance of triglyceride.
• LIPITOR reduces low-density lipoprotein in a population that rarely responds to other lipid-lowering drug (familial hypercholesterolemia).
• LIPITOR reduces total cholesterol, VLDL-C, TG and apo B in non-familial forms of hypercholesterolaemia and mixed dyslipidaemia.
It is used to treat atherosclerosis, reducing the risk of heart attacks and other cardiovascular complications, especially in people with coronary heart disease, type II diabetes and other high risk factors. The highest risk of atherosclerosis is present in people suffering from diabetes mellitus.
A study made by a group of doctors ( M. Saeed Arayne, Najma Sultana, University of Karachi, Pakistan,1990) compared LIPITOR with biguanides and proved LIPITOR as the most effective lipid-lowering agent, that, along with an antidiabetic activity, it obviously reduces the cardiac attack risk.
NEWS HIGHLIGHTS ABOUT LIPITOR
New Data from New University of Georgia (S. Matragoon, B. A. Pillai, 2011). Scientists report that LIPITOR prevents blindness in patients with diabetes, due to its action on free radicals in the retina.
Another interesting finding about LIPITOR was presented by a group of scientists at the 59th Annual Scientific Session of the American College of Cardiology(Dr. Prakash Deedwania, 2010). Their study shows that LIPITOR 80 mg lead to a significant reduced risk of cardiovascular events compared with LIPITOR 10 mg. As always, the dose of LIPITOR depends on a number of factors, including: age, medical history, other drugs intake, etc. The starting dose of LIPITOR for most people is 10 mg to 20 mg once a day. After a thorough cholesterol level check after 2-3 weeks, the dose may be increased up to 40 mg per day.
Clinical studies (Sever PS, Dahl?f B, Poulter NR.,2003) made by Anglo-Scandinavian Cardiac Outcomes Trial, based on more than 10.000 hypertensive patients showed that LIPITOR significantly reduces the rate of coronary events.
The risk reduction was consistent regardless of age, smoking status and obesity. LIPITOR has a lot of protective effects; scientists reported a significant reduction of myocardial infarct risk in the acute myocardial infarction administration.
The Department of Cardiovascular Medicine (Charalambos Antoniades,2011) from the University of Oxford conducted a randomized, placebo-controlled study and arrived at the conclusion that preoperative LIPITOR treatment rapidly improves vein graft redox state by inhibition NADPH-oxidase activity.
Another groups of scientists, including Oswaldo Valencia, MD (St George's Hospital, London, United Kingdom, 2010) pointed out the preventative effect of LIPITOR on postoperative atrial fibrillation.
DRUG AND FOOD INTERACTIONS:
Healthcare Professional updated the drug and food interaction section for LIPITOR. These are related to drug interactions and the risk of hemorrhagic stroke in patients with history of stroke. Some interactions may occur in reaction with food like herbs- red yeast rice and grapefruit, which contains substances that inhibit the body’s ability to break down LIPITOR.
A lot of studies have shown that LIPITOR has negative side effects, including extreme muscle pains, muscle disease and severe liver problems.
The patient should be treated symptomatically.
1. LIPITOR. (2009). [Electronic version]. e-CPS. Retrieved June 30, 2009.
2. Joseph Tuazon, PharmD. Medical Information Manager, Pfizer U.S. Medical Information. NDA (New Drug Application) studies. Changes in Memory and Cognition with Tables 1&2. Pfizer Inc. 182 Tabor Road, Morris Plains, NJ 07950, 14 June 2006.
3. Pregenzer JF, McKim JM Jr, Wilga PC. Anti-hypercholesterolemia drugs in the statin class reduce glutathione levels and increase caspase 3 activation in an in vitro cell model.
4. Mootha V et al. New chemical toolkit manipulates mitochondria, reveals insights into drug toxicity. Nat Bio. Epub February 24, 2008.
5. Goldberg AC, Ostlund RE Jr, Bateman JH, et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006;97:376–9.
6. Reszka, A.A., & Rodan, G.A. (2003). Bisphosphonate mechanism of action. Current Rheumatology Reports, 5(1), 65-74. PMID: 12590887
7. Schmidt, E.B., & Larsen, M.L. (2004). HMG-CoA-reductase-inhibitors. In S. Offermanns, & W. Rosenthal (Eds.). Encyclopedic reference of molecular pharmacology (pp. 460-463). Berlin, Germany: Springer.
Lipitor Review Article